Cyclacel Announces Discovery Of Aurora Kinase Inhibitors

Cyclacel Group plc ("Cyclacel"), the UK-based biopharmaceutical company, announced the discovery of a novel series of small molecule, cell cycle drugs inhibiting Aurora kinase in a poster presentation at the American Association for Cancer Research (AACR) Cell Cycle and Cancer: Pathways and Therapies conference taking place here. Cyclacel has advanced a lead compound from this series into preclinical development and is studying several fast-follower candidates.